Loading…
A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail
Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jia...
Saved in:
Published in: | Medicine (Baltimore) 2020-04, Vol.99 (16), p.e19757-e19757 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573 |
container_end_page | e19757 |
container_issue | 16 |
container_start_page | e19757 |
container_title | Medicine (Baltimore) |
container_volume | 99 |
creator | Pan, Xiaoting Tao, Heyun Nie, Mengjun Liu, Yuanjie Huang, Pan Liu, Shenlin Sun, Wei Wu, Jian Ma, Ting Dai, Anwei Lu, Jianwei Liu, Baorui Zou, Xi Sun, Qingmin |
description | Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction.
This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail.
This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147. |
doi_str_mv | 10.1097/MD.0000000000019757 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7220101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2393054518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573</originalsourceid><addsrcrecordid>eNpdUsuOFCEUJUbjjK1fYGJYupgaeRRFlwuTTo-vZCZudE0oHt0oBSVQPWn_1j-Rnm7HBxu4l3POvRwuAM8xusSo569uri7Rn4V7zvgDcI4Z7RrWd-1DcI4QYQ3veXsGnuT8tYIoJ-1jcEYJxZXQnYOfK6i8C05JD3OZ9R5GC0uS2hUXQ02uty6YbOBotFP1CKcUfQwbFzawbA3Mc9q5XQVWntQ7GZTRcCNzSU5BdQgTnGRxJpQMhz1MZjP7Gp_obhznEPM8Tcnk7HYGKuM9nOJ0h4rhNVydGquFS1TRQxsTlHCcfXGqypp0AZMMOo7uR62tYii1RV-P9R3OPwWPrPTZPDvtC_Dl3dvP6w_N9af3H9er60ZRxlCjuTHSEq07rTBVatkzqemAlzVcqqEjiJllxy0fOstoaztrjTUYDz3hqFpPF-DNUXeah2rWobMkvZiSG2Xaiyid-PcmuK3YxJ3ghCBcv2YBXp4EUvw-m1zE6PLBDRlMnLMgtKeItQwvK5QeoSrFnJOx92UwEofhEDdX4v_hqKwXf3d4z_k9DRXQHgG30Vdb8zc_35oktkb6sr3TY7wnDUEEoRZz1NRMh-gvalbN4A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393054518</pqid></control><display><type>article</type><title>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</title><source>PubMed Central (Open Access)</source><source>HEAL-Link subscriptions: Lippincott Williams & Wilkins</source><source>IngentaConnect Journals</source><creator>Pan, Xiaoting ; Tao, Heyun ; Nie, Mengjun ; Liu, Yuanjie ; Huang, Pan ; Liu, Shenlin ; Sun, Wei ; Wu, Jian ; Ma, Ting ; Dai, Anwei ; Lu, Jianwei ; Liu, Baorui ; Zou, Xi ; Sun, Qingmin</creator><creatorcontrib>Pan, Xiaoting ; Tao, Heyun ; Nie, Mengjun ; Liu, Yuanjie ; Huang, Pan ; Liu, Shenlin ; Sun, Wei ; Wu, Jian ; Ma, Ting ; Dai, Anwei ; Lu, Jianwei ; Liu, Baorui ; Zou, Xi ; Sun, Qingmin</creatorcontrib><description>Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction.
This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail.
This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000019757</identifier><identifier>PMID: 32311976</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Drugs, Chinese Herbal - pharmacology ; Drugs, Chinese Herbal - therapeutic use ; Humans ; Medicine, Chinese Traditional ; Multicenter Studies as Topic ; Phytotherapy ; Randomized Controlled Trials as Topic ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - immunology ; Stomach Neoplasms - mortality ; Study Protocol Clinical Trial</subject><ispartof>Medicine (Baltimore), 2020-04, Vol.99 (16), p.e19757-e19757</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220101/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220101/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32311976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Xiaoting</creatorcontrib><creatorcontrib>Tao, Heyun</creatorcontrib><creatorcontrib>Nie, Mengjun</creatorcontrib><creatorcontrib>Liu, Yuanjie</creatorcontrib><creatorcontrib>Huang, Pan</creatorcontrib><creatorcontrib>Liu, Shenlin</creatorcontrib><creatorcontrib>Sun, Wei</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Ma, Ting</creatorcontrib><creatorcontrib>Dai, Anwei</creatorcontrib><creatorcontrib>Lu, Jianwei</creatorcontrib><creatorcontrib>Liu, Baorui</creatorcontrib><creatorcontrib>Zou, Xi</creatorcontrib><creatorcontrib>Sun, Qingmin</creatorcontrib><title>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction.
This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail.
This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.</description><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Medicine, Chinese Traditional</subject><subject>Multicenter Studies as Topic</subject><subject>Phytotherapy</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - immunology</subject><subject>Stomach Neoplasms - mortality</subject><subject>Study Protocol Clinical Trial</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdUsuOFCEUJUbjjK1fYGJYupgaeRRFlwuTTo-vZCZudE0oHt0oBSVQPWn_1j-Rnm7HBxu4l3POvRwuAM8xusSo569uri7Rn4V7zvgDcI4Z7RrWd-1DcI4QYQ3veXsGnuT8tYIoJ-1jcEYJxZXQnYOfK6i8C05JD3OZ9R5GC0uS2hUXQ02uty6YbOBotFP1CKcUfQwbFzawbA3Mc9q5XQVWntQ7GZTRcCNzSU5BdQgTnGRxJpQMhz1MZjP7Gp_obhznEPM8Tcnk7HYGKuM9nOJ0h4rhNVydGquFS1TRQxsTlHCcfXGqypp0AZMMOo7uR62tYii1RV-P9R3OPwWPrPTZPDvtC_Dl3dvP6w_N9af3H9er60ZRxlCjuTHSEq07rTBVatkzqemAlzVcqqEjiJllxy0fOstoaztrjTUYDz3hqFpPF-DNUXeah2rWobMkvZiSG2Xaiyid-PcmuK3YxJ3ghCBcv2YBXp4EUvw-m1zE6PLBDRlMnLMgtKeItQwvK5QeoSrFnJOx92UwEofhEDdX4v_hqKwXf3d4z_k9DRXQHgG30Vdb8zc_35oktkb6sr3TY7wnDUEEoRZz1NRMh-gvalbN4A</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Pan, Xiaoting</creator><creator>Tao, Heyun</creator><creator>Nie, Mengjun</creator><creator>Liu, Yuanjie</creator><creator>Huang, Pan</creator><creator>Liu, Shenlin</creator><creator>Sun, Wei</creator><creator>Wu, Jian</creator><creator>Ma, Ting</creator><creator>Dai, Anwei</creator><creator>Lu, Jianwei</creator><creator>Liu, Baorui</creator><creator>Zou, Xi</creator><creator>Sun, Qingmin</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200401</creationdate><title>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</title><author>Pan, Xiaoting ; Tao, Heyun ; Nie, Mengjun ; Liu, Yuanjie ; Huang, Pan ; Liu, Shenlin ; Sun, Wei ; Wu, Jian ; Ma, Ting ; Dai, Anwei ; Lu, Jianwei ; Liu, Baorui ; Zou, Xi ; Sun, Qingmin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Medicine, Chinese Traditional</topic><topic>Multicenter Studies as Topic</topic><topic>Phytotherapy</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - immunology</topic><topic>Stomach Neoplasms - mortality</topic><topic>Study Protocol Clinical Trial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Xiaoting</creatorcontrib><creatorcontrib>Tao, Heyun</creatorcontrib><creatorcontrib>Nie, Mengjun</creatorcontrib><creatorcontrib>Liu, Yuanjie</creatorcontrib><creatorcontrib>Huang, Pan</creatorcontrib><creatorcontrib>Liu, Shenlin</creatorcontrib><creatorcontrib>Sun, Wei</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Ma, Ting</creatorcontrib><creatorcontrib>Dai, Anwei</creatorcontrib><creatorcontrib>Lu, Jianwei</creatorcontrib><creatorcontrib>Liu, Baorui</creatorcontrib><creatorcontrib>Zou, Xi</creatorcontrib><creatorcontrib>Sun, Qingmin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Xiaoting</au><au>Tao, Heyun</au><au>Nie, Mengjun</au><au>Liu, Yuanjie</au><au>Huang, Pan</au><au>Liu, Shenlin</au><au>Sun, Wei</au><au>Wu, Jian</au><au>Ma, Ting</au><au>Dai, Anwei</au><au>Lu, Jianwei</au><au>Liu, Baorui</au><au>Zou, Xi</au><au>Sun, Qingmin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>99</volume><issue>16</issue><spage>e19757</spage><epage>e19757</epage><pages>e19757-e19757</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction.
This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail.
This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>32311976</pmid><doi>10.1097/MD.0000000000019757</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-7974 |
ispartof | Medicine (Baltimore), 2020-04, Vol.99 (16), p.e19757-e19757 |
issn | 0025-7974 1536-5964 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7220101 |
source | PubMed Central (Open Access); HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals |
subjects | Drugs, Chinese Herbal - pharmacology Drugs, Chinese Herbal - therapeutic use Humans Medicine, Chinese Traditional Multicenter Studies as Topic Phytotherapy Randomized Controlled Trials as Topic Stomach Neoplasms - drug therapy Stomach Neoplasms - immunology Stomach Neoplasms - mortality Study Protocol Clinical Trial |
title | A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A27%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20clinical%20study%20of%20traditional%20Chinese%20medicine%20prolonging%20the%20survival%20of%20advanced%20gastric%20cancer%20patients%20by%20regulating%20the%20immunosuppressive%20cell%20population:%20A%20study%20protocol%20for%20a%20multicenter,%20randomized%20controlled%20trail&rft.jtitle=Medicine%20(Baltimore)&rft.au=Pan,%20Xiaoting&rft.date=2020-04-01&rft.volume=99&rft.issue=16&rft.spage=e19757&rft.epage=e19757&rft.pages=e19757-e19757&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000019757&rft_dat=%3Cproquest_pubme%3E2393054518%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2393054518&rft_id=info:pmid/32311976&rfr_iscdi=true |